Harnish Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.82 Cr
- Paid Up Capital ₹ 2.82 Cr
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 6.10 Cr
- Revenue Growth 140.37%
- Profit Growth 208.39%
- Ebitda 10429.09%
- Net Worth 18.59%
- Total Assets 4.21%
About Harnish Pharma
Harnish Pharma Private Limited (HPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 April 2018 (Six years and nine months 14 days old ). Its registered office is in Mahesana, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.82 Cr and a paid-up capital of Rs 2.82 Cr.
The company has closed loans amounting to ₹6.10 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jaspal Chaudhary and Ramiben Chaudhari serve as directors at the Company.
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U36999GJ2018PTC101875
- Company No.
101875
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Apr 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Harnish Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jaspal Chaudhary  | Director | 17-Apr-2018 | Current |
| Ramiben Chaudhari | Director | 17-Apr-2018 | Current |
Financial Performance of Harnish Pharma.
Harnish Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 140.37% increase. The company also saw a substantial improvement in profitability, with a 208.39% increase in profit. The company's net worth Soared by an impressive increase of 18.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Harnish Pharma?
In 2021, Harnish Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹6.10 Cr
Charges Breakdown by Lending Institutions
- Sidbi : 6.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Nov 2019 | Sidbi | ₹5.10 Cr | Satisfied |
| 11 Nov 2019 | Sidbi | ₹1.00 Cr | Satisfied |
How Many Employees Work at Harnish Pharma?
Harnish Pharma has a workforce of 32 employees as of Sep 24, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Harnish Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Harnish Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
